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A B S T R A C TObjective: Mood disorders are associated with a high societal cost,
mainly due to presenteeism. The objective of this study was to review
the use of 10 instruments that rate presenteeism in mood disorders
and to provide recommendations regarding the appropriateness of
instruments in different study settings. Methods: A systematic
review of the literature was conducted to identify scales used to
measure presenteeism, including the World Health Organization
Health and Work Performance Questionnaire, the Lam Employment
Absence and Productivity Scale, the Sheehan Disability Scale, the
Work Limitation Questionnaire, and Work Productivity and Activity
Impairment questionnaire. Study characteristics and major results (by
symptom level, by treatment arm, correlation to other scales, and use
of monetization) were data extracted. Results: Twenty-nine studies
were identified. The Sheehan Disability Scale, the Work Limitation
Questionnaire, and Health and Work Performance Questionnaire were
the most commonly used instruments. The majority (60%) of scales
demonstrated higher presenteeism in individuals with mood disor-
ders than in individuals without. The Lam Employment Absence andnt matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.08.2206
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ondence to: Nicolas Despie´gel, OptumInsight, 41 ruProductivity Scale, the Sheehan Disability Scale, and the Work
Limitation Questionnaire showed that presenteeism increased with
increasing severity of disease. Few studies reported results on pre-
senteeism by treatment, with only small between-treatment differ-
ences observed. Good correlations between presenteeism instruments
and clinical or quality-of-life scales were reported. Three studies
converted results from presenteeism scales into monetary units.
Conclusions: Limited experiential evidence exists comparing the
performance of presenteeism scales in mood disorders. Therefore,
recommendations for inclusion of a presenteeism tool must be driven
by instrument properties (ease of administration, amenability to
monetization) and the study type. Future research should focus on
the responsiveness of the instrument and on how mood disorders
impact self-reported assessment.
Keywords: mood disorders, presenteeism, productivity, self-report.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Mood disorders include major depressive disorder in which
patients experience one or several depressive episodes or bipolar
disorder, characterized by intermittent episodes of mania or
hypomania, usually interspersed with depressive episodes. These
conditions are associated with a high societal cost, primarily due
to productivity losses [1]. Mood disorders lead to higher unem-
ployment, absence, and turnover rates as well as higher at-work
performance deficits (or presenteeism). Presenteeism is defined as
‘‘the decrease in productivity for the much larger group of
employees whose health problems have not necessarily led to
absenteeism and the decrease in productivity for the disabled
group before and after the absence period’’ [2].
For some disorders, presenteeism is an even greater cause of
productivity loss than absenteeism (i.e., migraine, seasonal aller-
gies). Although the cost of presenteeism is not routinely esti-
mated in economic evaluations, it is estimated to account for 54%
to 82% of the total lost productivity in employees with mooddisorders, as observed in US workers by using the World Health
Organization Health and Work Performance Questionnaire (HPQ)
or the Work and Health Interview[3,4]. These values, however,
may overestimate the true impact because they do not account
for the hiring and training of replacement workers. The relative
importance of presenteeism compared with absenteeism in this
disease area is likely because individuals with depression or
anxiety tend to stay at work and perform suboptimally rather
than take sick leave [4,5].
Productivity loss due to absenteeism is often taken into
account in economic evaluations that adopt a societal perspec-
tive and is measured simply by counting the number of days off
work; measuring productivity loss due to presenteeism, on the
other hand, is more complex. First, the evaluation of presentee-
ism requires the estimation of a ‘‘normal productive output’’ for a
given individual in a given role, after which the impairment in
productive output may be quantified [6]. Second, reduction in
symptoms reduces absenteeism, but its impact on presenteeism
is more uncertain [7,8]. Third, depression affects productivityfor Pharmacoeconomics and Outcomes Research (ISPOR).
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aspects of productivity more typically impaired in different
professions [9]. For example, in jobs in which individuals have
to exercise judgment such as nurses, engineers, social workers,
marketing managers, attorneys, and financial analysts, depressed
workers may experience limitations on output demands (handle
workload, work fast enough, meet simultaneous demand, etc.)
and be more absent. In jobs with a high degree of contact such as
teachers, customer service managers, sales people, and consul-
tants, workers may have limitations in handling mental (keep
mind on work, think clearly, do precise work, handle demanding/
stressful work, etc.), interpersonal (speak on the phone, commu-
nicate well, maintain contacts, etc.), and physical (lift/carry/move
objects, use handled tools/equipment, get to work from parking/
bus/train, etc.) demands. Fourth, the impact on presenteeism is
directly related to the nature of the depressive symptoms presented
by the patient. According to Lerner et al. [9], concentration difficul-
ties and distractibility lead to lower overall productivity, whereas
tiredness and sleep disturbance induce higher absence and pro-
blems with mental, interpersonal, time (getting to work, work
without breaks or rests, adjusting to work pace changes, etc.), and
output demands. Finally, while self-report instruments have been
developed to evaluate presenteeism, they run the risk of presenting
biased and different results compared with objectively measured
time lost at work. Stewart et al. [10] demonstrated that self-reported
time spent working was higher than that which was obtained when
evaluating official workplace data on time absent, time away from
desk, and electronic continuous performance data specific to the
workplace. Other researchers state that self-reported evaluations
might lead to an overestimation of lost productivity due to pre-
senteeism [11] because subjective feelings of high discomfort may
cause employees to report lower productivity even if their tasks
have been completed successfully. Moreover, depression can influ-
ence the self-reporting of productivity because of a loss of concen-
tration, attention, and/or motivation [12] or cognitive deficits [13].
The selection of the appropriate self-report instrument should
be based on both its ability to translate health states into at-work
productivity estimates and its relevance to the study setting and
objectives, that is, whether the objective is to assess the impact
of the disease on aspects of work performance or to estimate the
economic consequences of the disease. The optimal self-report
instrument needs to be sufficiently sensitive to detect the effects
of treatment interventions.
Several reviews have previously been published with the aim
of evaluating instruments used to assess presenteeism. Prasad
et al. [14] published an extensive review of the psychometric
properties of productivity instruments, assessing their validity,
reliability, responsiveness, generalizability, and ease of adminis-
tration. Evidence on psychometric properties from this and other
studies has been provided to various degrees depending on the
nature of the instrument. Prasad et al. concluded that the Work
Limitation Questionnaire (WLQ) and the Work Productivity and
Activity Impairment (WPAI) questionnaire offer the most signifi-
cant advantages with good psychometric properties, being ready,
and easy to use in various study settings (e.g., clinical studies and
employee populations). Lofland et al. [15] and Mattke et al. [16]
assessed the psychometric properties of available instruments
and the ability of each instrument to provide monetary esti-
mates. The authors of both studies concluded that the main
hurdle currently relates to the absence of established and
validated methods for monetization of productivity estimates. A
more recent review by Brooks et al. [17] discussed several issues
related to measurement. The authors emphasized the limitations
related to the conversion into economic outcomes and advocated
against evaluating productivity at an individual level. Lerner and
Henke [12] assessed the impact of depression on lost productivity,
reviewing the four most widely used self-report instruments toassess presenteeism in this disease area and their use in various
settings (e.g., population-based studies, workplace studies, and
clinical studies). They concluded that the WLQ was the most
appropriate instrument for accurately measuring work produc-
tivity in individuals with depression.
Because of the importance of productivity losses in mood
disorders and the challenges for their estimation, the selection of
the appropriate tool to measure presenteeism is essential. Because
three of the existing reviews did not relate to mood disorders and
the fourth, considering depression, reviewed only a subset of the
available instruments, the objective of this article was to review and
discuss the scales available for assessing presenteeism related to
mood disorders. We extend the work by Lerner et al [12]. by
including six additional instruments and more recently published
articles of randomized clinical trials (RCTs) and observational
studies. We also provide recommendations on the use of produc-
tivity scales in the area of mood disorders.Methods
Identifying Instruments That Evaluate Presenteeism
Taking the four most recent reviews detailing rating scales measur-
ing presenteeism, we evaluated all reported scales, all of which
were self-report instruments. In addition to the initial pool of 20
scales, a more recent scale not mentioned in any of the four reviews
and a disability scale with a presenteeism component were eval-
uated. Instruments were selected according to the following inclu-
sion/exclusion criteria (Table 1). All scales should be generic or
specific to mood disorders, demonstrate (at least partially) good
psychometric properties, and be applicable to any type of worker. It
should be possible to use these instruments to measure presentee-
ism in studies such as RCTs or prospective observational studies;
nongeneral instruments or techniques (applicable to a specific
study design or a specific worker category) were excluded. Generic
instruments that were used in a limited number of disease areas
other than mood disorders were also excluded. Ten instruments
were finally considered. Among the 10 excluded instruments, 7
were specific to a disease area other than mood disorders.
Two categories of instruments were defined: (1) instruments
that are amenable to monetization (with specific development
regarding this matter or with published experience on conversion
into monetary units) and (2) instruments that cannot be used to
monetize productivity loss. This article briefly addresses the major
characteristics and psychometric properties, as well as the methods
for monetization. Full details regarding the major domains of the
scales, how each instrument assesses presenteeism, major proper-
ties, possibility for conversion into monetary units, and use
reported in the literature are provided in Table 2 [10,18–29].Health & Labour Questionnaire/Short Form Health & Labour
Questionnaire
The Health & Labour Questionnaire (HLQ) gathers data regarding
reduction in work performance due to illness [28,29]. It consists of
four modules that assess (1) workplace absenteeism, (2) workplace
presenteeism, (3) unpaid work, and (4) impediments to paid and
unpaid work. Workplace presenteeism is measured as the number
of additional hours that should have been worked to compensate
for production losses due to illness at work. Individuals also provide
responses to questions designed to determine specific productivity
problems (e.g., concentration difficulties) related to presenteeism. A
short-form version of the HLQ (SF-HLQ) has also been developed and
comprises three modules: absenteeism from paid work, production
losses without absenteeism from paid work, and hindrance in the
performance of paid and unpaid work [19].
Table 1 – Selection of presenteeism instruments.
Instruments Selected
in the
review
Generic Specific
to mood
disorder
Specific to other
disease areas
Generic but tested in
a limited number of
other disease areas
Not applicable
to any employee
Not applicable to
studies in mood
disorders
ALWQ Angina
EWPS X
HAQ/HAQ-II Rheumatoid arthritis
HLQ/SF-HLQ X
HPQ X X
HRPQ-D Parkinson’s disease,
infectious
mononucleosis
HWQ X X
LEAPS X
MIDAS Migraine
MWPLQ Migraine
Osterhaus technique Migraine
SDS X X
SPS X X
Unnamed hepatitis
instruments
Hepatitis
WHI X X
WIS Rheumatoid arthritis
and traumatic
brain injury
WLQ X X
The WPAI questionnaire X X
WPI X Call centers
WPSI Used to inform on the relative
importance of health
conditions that affect
productivity at work for a large
group of employees
EWPS, Endicott Work Productivity Scale; HLQ/SF-HLQ, Health & Labour Questionnaire/Short-form Health and Labour Questionnaire; HPQ, Health and Work Performance Questionnaire; HWQ,
Health and Work Questionnaire; LEAPS, Lam Employment Absence and Productivity Scale; MIDAS, Migraine Disability Assessment;; MWPLQ, Migraine Work and Productivity Loss
Questionnaire; SDS, the Sheehan Disability Scale; SPS, Stanford Presenteeism Scale; WHI, Work and Health Interview; WLQ, Work Limitations Questionnaire; WPAI, Work Productivity and
Activity Impairment; WPI, Worker Productivity Index; WPSI, Work Productivity Short Inventory.
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Table 2 – Summary of productivity measurement instruments.
Instrument Assessments Assessment and
scoring:
presenteeism
Recall period and
estimated time to
complete
Psychometric properties Option for
monetization
Content
validity
Construct
validity
Reli-
ability
Respon-
siveness
Instruments amenable to monetization
Health & Labour
Questionnaire
(HLQ)
Workplace
absenteeism,
workplace
presenteeism,
unpaid work,
impediments to
work and unpaid
work
[Employed] level of
impediment while
working on a 0–10 scale
Recall: 2 wk Convergent
discriminant
Specified
Number of questions:
10 items (short-form
version)
Time to complete: Not
reported
Health and Work
Performance
Questionnaire
(HPQ)
Presenteeism,
absenteeism,
accident/injuries
Absolute presenteeism:
actual performance on a
1–100 scale
Recall: 7 d or 4 wk
Number of questions:
13 items (7-d RCT
version)
Time to complete: Not
reported
Yes
Cognitive
debriefing
Convergent
discriminant
Internal Specified. Absolute
measures should
be used because
relative score of
presenteeism can
be41
Relative presenteeism:
ratio of actual
performance to the
performance of most
workers at the same job,
as reported by the
respondent
’Health and Work
Questionnaire
(HWQ)
Productivity,
impatience/
irritability,
concentration,
work
satisfaction,
satisfaction with
supervisor,
personal life
satisfaction
Efficiency, quality, and
amount of work
completed over the
recall period on a 0–10
scale
Recall: 1 wk
Number of questions:
27 questions
Time to complete: Not
reported
Convergent Internal HWQ responses
could be
interpreted as a
percentage
reduction in
normal
productivity,
though there is no
example of
monetization of
this scale in the
recent literature
Indication of how a
supervisor and a
coworker would respond
to the same questions
about the respondents’
productivity
Work and Health
Interview (WHI)
Absenteeism,
presenteeism,
time spent caring
for ill family
members, salary
from paid
employment
Concentration loss while
unwell, repeated a job
while unwell, worked
more slowly while
unwell, felt fatigue while
unwell. % of
effectiveness while ill
(from categorical
responses on
presenteeism)
Recall: 2 wk Number of
questions: 25 questions
Time to complete: Not
reported
Convergent Specified. But defined
from the
conversion of
categorical
response into an
effectiveness score
Work Limitations
Questionnaire
(WLQ)
Time management.
physical. mental-
interpersonal.
output
Average of the four
domains to productivity-
related questions and
converting the average
to an interval scale to
achieve a 0–100 scale of
productivity
Recall: 2 wk Yes Content
developed
including
depressed patients
Cognitive
debriefing
Convergent
discriminant
Internal Not explicitly
specified. Would be
defined from the
conversion of
categorical
response into an
effectiveness score
Number of questions: 25
questions
Time to complete: Not
reported
Work
Productivity
and Activity
Impairment
(WPAI)
questionnaire
Absenteeism,
presenteeism,
usual activities
impairment
Self-reported work
performance is assessed
with a 0–100 visual
analogue scale
Recall: 7 d Cognitive debriefing Convergent
discriminant
Test-retest Yes Specified
Number of questions: Six
questions
Time to complete: Not
reported
Lam Employment
Absence and
Absenteeism,
productivity
impairment
Total impairment score on
a 0–28 scale (level of
energy, concentration,
Recall: 2 wk Convergent
discriminant
Internal Yes, using a subscore
including the three
Likert items
Number of questions: 10
items
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Table 2 – (continued)
Instrument Assessments Assessment and
scoring:
presenteeism
Recall period and
estimated time to
complete
Psychometric properties Option for
monetization
Content
validity
Construct
validity
Reli-
ability
Respon-
siveness
Productivity
Scale (LEAPS)
related to mental
health–related
problems
anxiety). This scale could
be interpreted as a
presenteeism measure
related exclusively
to problems at
work
Time to complete: 3–5
min
Instruments not amenable to monetization
Endicott Work
Productivity
Scale (EWPS)
Behaviors,
subjective
feelings or
attitudes
Frequency of productive
behaviors during the
previous 1 wk using a
five-point Likert scale. A
sum of scores is
computed, ranging from
0 (best score) to 100
(worst score)
Recall: 1 wk Convergent
discriminant
Internal test
retest
No. No obvious link
between the score
and % productivity,
which prevents
obvious
monetization
Number of questions: 25
items
Time to complete: Not
reported
Sheehan Disability
Scale (SDS)
Work/school
impairment,
social life
impairment,
family life
impairment,
number of days
unable to attend
work or school
because of
symptoms,
number of days
underproductive
due to symptoms
Rate (0–10 scale) on how
symptoms have
disrupted work or school
work Number of days
‘‘underproductive’’ due
to symptoms
Recall: 1 wk, 1 mo, or 3
mo
Convergent
discriminant
Internal test-
retest
Yes No. The question on
how symptoms
have disrupted
work or
schoolwork
includes
absenteeism The
number of days
underproductive
has no link with
the previous
assessment
Number of questions: Five
items
Time to complete: Not
reported
Stanford
Presenteeism
Scale (SPS)
Stress, focus,
energy at work
Stress, focus, energy at
work, no global score
combining these
attributes
Recall: 1 mo Convergent
discriminant
Internal No
Number of questions: Six
items
Time to complete: Not
reported
RCT, randomized controlled trial.
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Questionnaire
The HPQ is a self-report instrument designed to estimate the
consequence of health problems on job performance, sickness
absence, and work-related accidents and injuries [20]. Presentee-
ism as measured by the HPQ is a measure of actual performance
in relation to possible performance. Respondents are asked to
rate normal and impaired performance in their job on a scale of 1
to 10, understood as ‘‘percentage effectiveness,’’ for the purposes
of scoring and monetizing presenteeism. Absolute presenteeism
has a lower bound of 0 (or 0% effectiveness during hours worked)
and an upper bound of 100 (or perfect effectiveness during hours
worked). Relative presenteeism is measured as the ratio of actual
performance to the performance of most workers in the same
job. The instrument’s developers recommend restricting the
measure of relative presenteeism from 0.25 to 2.0, where 0.25 is
the worst relative performance (25% or less of other workers’
performance) and 2.0 is the best performance (200% or more of
other workers’ performance).
Health and Work Questionnaire
The Health and Work Questionnaire is a multidimensional
measure of productivity. Its domains measure productivity,
impatience/irritability, concentration, work satisfaction, satisfac-
tion with supervisor, and personal life satisfaction [26]. Presen-
teeism measures the efficiency, quality, and amount of work
completed over the recall period on a 0 to 10 scale. Respondents
are also asked to give an indication of how a supervisor and
coworker would respond to the same questions as to the
respondent’s productivity.
Work and Health Interview
The Work and Health Interview is a questionnaire that provides a
measurement of productive time lost because of work absence
and reduced performance at work [10,27]. Presenteeism is mea-
sured as the number of days in the previous 2 weeks the
respondent worked while ill. Four questions require respondents
to report how often, on average, they (1) lost concentration, (2)
repeated a job, (3) worked more slowly, and 4) felt fatigued on
days they attended work while feeling unwell. Response options
are categorical (‘‘all of the time,’’ ‘‘most of the time,’’ ‘‘half of the
time,’’ ‘‘some of the time,’’ and ‘‘none of the time’’). In Stewart
et al. [10] these categorical responses were converted to percen-
tages for monetization (‘‘all of the time’’ ¼ 100%, ‘‘most of the
time’’ ¼ 75%, through ‘‘none of the time’’ ¼ 0%).
Work Limitation Questionnaire
The WLQ is a 25-item questionnaire designed to measure the
impact of chronic disease on work performance [23]. The 25
items of the WLQ are grouped into four scales: (1) time manage-
ment, (2) physical, (3) mental-interpersonal, and (4) output. The
scale scores represent the amount of time in the past 2 weeks
that an individual was limited on the job. To create a score for
each scale, the questionnaire’s categorical responses are con-
verted to an interval scale. The average scores for items within
each scale are summed, divided by the total number of scale
items, and then multiplied by a factor of 25 (WLQ ‘‘Scale Score’’):
WLQ Scale Score ¼ 25(average item score  1)
The scale scores calculated from the four scale scores range
from ‘‘0’’ (least limited) to ‘‘100’’ (most limited). A score of ‘‘50,’’ for
example, indicates that the individual was limited in performing
work demands during 50% of the reporting period. Another score,
the WLQ ‘‘Productivity Loss Index,’’ has been developed [30] as the
weighted sum of scale scores and retransformed into a WLQ
‘‘Productivity Loss Score,’’ which corresponds to ‘‘the estimatedpercent difference in an employee’s at-work productivity com-
pared to employees who do not have health-related work limita-
tions.’’ This represents a percent reduction in output in the past
2 weeks compared with the output of a healthy (not limited)
employee. The weights used are empirically based statistical
estimates relating self-report scores to objectively measured
productivity.
Work Productivity and Activity Impairment
The WPAI questionnaire consists of six questions that ask
respondents to identify the number of hours missed from work
and usual activities, as well as the degree to which work or
regular daily activities were limited over the past 7 days [24,25].
The questionnaire yields four scores: (1) percentage of work time
missed because of ill health, (2) percentage impairment while
working due to ill health, (3) percentage activity impairment
due to ill health, and (4) an overall percentage work impairment
score due to health problems. The four scores are expressed as
‘‘impairment percentages,’’ where higher numbers reflect greater
impairment and decreased productivity.
Lam Employment Absence and Productivity Scale
LEAPS is a 10-item self-report questionnaire developed to assess
work functioning and impairment in a clinically depressed
population [21]. It includes a component related to absenteeism
(based on two items inquiring as to the number of scheduled
work hours and work hours missed) and another related to
presenteeism. The latter component consists of seven items
rated on a five-point Likert scale (‘‘none of the time’’ to ‘‘all of
the time’’), asking directly as to the most common problems
encountered at work (‘‘making more mistakes,’’ ‘‘doing poor
quality of work’’) and the clinical symptoms most associated
with work impairment (levels of energy, concentration, and
anxiety). The total score on the seven Likert items therefore
yields a global impression of impairment due to mental
health–related problems.
Endicott Work Productivity Scale
The EWPS is a 25-item questionnaire created to assess impair-
ment in employees with depression [18]. This instrument was
designed specifically to capture information on productivity loss
during clinical trials, measuring both absenteeism and presen-
teeism. The frequency of productive behaviors during the pre-
vious week is captured by using a five-point Likert scale
(anchored from 0 ¼ ‘‘Never’’ to 4 ¼ ‘‘Almost always’’), and a sum
of the scores is computed, ranging from 0 (best score) to 100
(worst score). The instrument lacks any obvious means to convert
employees’ scores directly into monetary units, limiting its
function to the relative ranking of employees according to
reported productivity impairment.
Sheehan Disability Scale
Although not specifically designed to measure presenteeism, the
Sheehan Disability Scale (SDS) assesses functional impairment in
three areas: work/school, social, and family experiences. For each
domain, a 10-point visual analogue scale with labels is used to
quantify the level of functional impairment [22,31,32]. The three
components of the questionnaire are then summed into a single
score that ranges from 0 (unimpaired) to 30 (highly impaired).
Two additional questions are used as part of the assessment: one
asks respondents to estimate the number of days they were less
than fully productive at work. It should be noted that there is no
direct link between this question and the assessment of the
functional impairment of activities at work/school. In other
words, the SDS could potentially provide spurious results if
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a ‘‘% effectiveness’’ scale for the number of days of impairment
reported. As a result, no monetization seems possible based on
the SDS evaluation.
Stanford Presenteeism Scale
The Stanford Presenteeism Scale 6 (SPS-6) is a six-item ques-
tionnaire [33], with each question linked to a Likert five-item
response scale ranging from ‘‘strongly disagree with the state-
ment’’ to ‘‘strongly agree with the statement.’’ No clear indication
is provided as to how the ordinal responses from individuals in
the SPS could be monetized. The scale is intended to rank
individuals according to impairment at work.
Instrument Validations
Prasad et al. [14], Lofland et al. [15], Mattke et al. [16], and Brooks et al.
[17] have published extensive reviews on the reliability and validity of
all available instruments measuring presenteeism, with the excep-
tion of the LEAPS scale. This scale, which was developed after these
reviews were published, has since been formally validated [21] and is
addressed in this article. In these reviews, information regarding
content validity has not been extensively addressed. Some aspects
related to the inclusion of patients with mood disorders during the
scale development and the use of cognitive debriefing are presented
further in this article. The summary of psychometric properties by
instrument is presented in Table 2.
The face validity of each instrument was evaluated by check-
ing the scale format and whether the recall period is appropriate
for this population. The 10 instruments present different
response formats, Likert scales being the most frequent. Some
instruments include questions leading to complex calculations.
For example, the HPQ asks the ‘‘Number of hours in the past 4
weeks’’ (B6) and includes detailed examples to guide the respon-
dent. The recall period ranges from 1 week to 1 month, but more
recent instruments tend to use a 2-week recall period. The main
challenge is to mitigate the recall bias without adding too many
additional assessments and increasing the burden of the study
[17,34]. SDS is primarily a functionality scale and not an instru-
ment to estimate presenteeism or productivity loss per se.
Three instruments (HPQ, WLQ, and the WPAI questionnaire)
reported details on the scale development beyond the fact that
item generation was based on a review of the literature. In
particular, reported cognitive debriefing was part of the scale
development that addressed one of the identified causes of bias
in self-reports in this population. This supports content validity
for these three instruments. In addition to the depression-
specific instruments (EWPS and LEAPS), only WLQ included
patients with depression as part of the scale development.
Construct validity is divided into convergent validity (instru-
ments measuring the same concepts should correlate with one
another) and discriminant validity (instruments measuring dif-
ferent concepts should not correlate with one another). Construct
validity has been established for all instruments categorized as
demonstrating either convergent validity or discriminant validity.
Reliability, which pertains to internal consistency (of items
within a domain), as well as interrater and test-retest reliability,
has been formally demonstrated for the Health and Work Ques-
tionnaire, LEAPS, WLQ, and EWPS. Because the focus for the SDS
is toward the work domain (comprising only one question), it is
not possible to assess the internal consistency of this instrument.
Responsiveness (the ability to assess clinically important change
over time) has been demonstrated for three instruments: the
WPAI questionnaire, WLQ, and SDS.
Because most of these instruments were not initially devel-
oped to assess mood disorders, it is important to assess their
suitability for use in this population to account for the specificimpact of depression on presenteeism. Only four instruments
have been partially or fully validated for use in this disease area:
psychometric properties have been investigated in major depres-
sive disorders for LEAPS [21], WLQ [5], and EWPS [18], while
validity has been fully assessed for the SDS in both major
depressive disorder [32] and bipolar disorder [35].
Monetization
The translation of scores derived from presenteeism instruments
to monetary units has been discussed extensively in Brooks et al.
[17]. This translation can be divided into two parts: the conver-
sion from a score into a quantifiable measure, such as lost time or
percentage of productivity lost, and the translation into monetary
units. Translations of presenteeism scales into monetary units
are detailed by Lofland et al. [15] and Brooks et al. [17] for HLQ,
HPQ, WLQ, the WPAI questionnaire, and the Worker Productivity
Index (WPI). Monetization of lost productivity due to presentee-
ism is not feasible in instruments producing a score that does not
represent (directly) impaired productivity (e.g., EWPS, SDS, and
SPS-6).
The HPQ appears to be the instrument best suited for conver-
sion into monetary units. This is due to the clear distinction that
is made by this instrument between absence for any reason and
absence due to ill health, enabling the quantification of the actual
lost productivity that was caused by the illness. Moreover, full
guidance on monetization and missing data handling is provided.
A major weakness in this instrument, however, is that some
questions can be very complex, especially in the context of mood
disorders.
While not considered in the review by Brooks et al. [17], LEAPS
allows for the generation of costs associated with presenteeism,
including the Likert items related exclusively to problems at work
(three items). These subscores have the potential for monetization,
for which the development and testing of a specific methodology is
under way by the scale developers. Further assessment of the
psychometric properties for these subscores in major depressive
disorder by comparing it against the HPQ is also planned.
In theory, the translation from WLQ into monetary units could
be achieved by using the WLQ ‘‘Scale Score’’ or the WLQ ‘‘Produc-
tivity Loss Score.’’ The former is restricted to one domain. While
the feasibility of monetization has not been explicitly mentioned
by the designers of the latter instrument, it was purposely created
to express the percentage productivity reduction in nonhealthy
individuals compared with healthy workers and is better suited to
generating monetary estimates of presenteeism because all the
domains are weighted according to their impact on objective
estimates. This is the only conversion algorithm derived by using
the relation to self-report measures to objective data.
Valuation of presenteeism is usually handled by applying the
human capital approach according to the formulae provided by
instrument developers or other research teams although this
does not account for the impact on other workers’ productivity.
The multiplier methods proposed by Pauly et al. [11] could be
applied to monetize this impact. The impact of using multipliers
to estimate the cost of presenteeism has been assessed in other
disease areas [36].
Review of the Use and Performance of Productivity Scales in
Mood Disorders
The use and performance of these instruments for assessing
productivity in mood disorders in RCTs and observational studies
was systematically reviewed by using PubMed. All articles pub-
lished before March 30, 2011, were selected by using keywords,
and this search was completed through a manual search. The
following characteristics for the identified studies were extracted:
Table 3 – Summary of information available in studies using productivity instruments in mood disorders.
Reference Title Type of
study
Productivity
scale
Other
scale
Result by
presence of
disorder
Result by
severity of
disorder
Result by
evolution of
disorder
Result by
treatment
arm
Correlation
to other
scales
Adler et al. [7] Job performance deficits
due to depression
OS WLQ PHQ-9
(depression),
SF-36
WLQ (output,
time,
mental)
 Depression
WLQ (output, time,
mental)  Improve-
ment
Ansseau et al.
[37]
Objective: remission of
depression in primary
care The Oreon Study
OS SDS HDRS7
(depression)
SDS work
 Remission
Arbuckle
et al. [35]
The psychometric
validation of the SDS in
patients with bipolar
disorder
OS SDS, the
WPAI
questionnaire
BFSQ
(bipolar), EQ-
5D, SF-36
SDS work 
Bipolar
severity
SDS work  (SDS
family; SDS social;
the WPAI
questionnaire
overall work
impairment; BFSQ;
MCS, EQ-5D)
Burton et al.
[13]
The association of
medical conditions and
presenteeism
OS WLQ WLQ (output,
time,
mental)
 Depression
Calabrese
et al. [38]
Impact of bipolar
disorder on a US
community sample
OS SDS SAS-SR, MDQ SDS work 
Bipolar
Calabrese
et al. [39]
Impact of depressive
symptoms compared
with manic symptoms
in bipolar disorder:
results of a US
community-based
sample
OS SDS SAS-SR, MDQ SDS work 
Depressive /
Manic
symptoms
Endicott and
Nee [18]
Assessment measures
for clinical studies
RCT (post
hoc)
EWPS SCL-90,
HAMD
(depression),
CGI
EWPS 
Depression
EWPS  (HAMD;
CGI)
Esposito et al.
[40]
Mood and anxiety
disorders, the
association with
presenteeism in
employed members of a
general population
sample
OS SPS MINI (mood
disorder)
SPS  Mood
disorders/
Anxiety /
Control
Greco et al.
[41]
The outcome of physical
symptoms with
treatment of depression
RCT WLQ (output,
time, mental)
PCP
Holden et al.
[42]
Psychological distress is
associated with a range
of high-priority health
conditions affecting
working Australians
OS HPQ†
Kamat et al.
[43]
Prevalence and
humanistic impact of
potential misdiagnosis
of bipolar disorder
among patients with
major depressive
Retro-
spective
claims
database
þ survey
data
SDS SF-12, MDQ
(Bipolar
disorder)
SDS work 
Bipolar
V
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Table 3 – (continued)
Reference Title Type of
study
Productivity
scale
Other
scale
Result by
presence of
disorder
Result by
severity of
disorder
Result by
evolution of
disorder
Result by
treatment
arm
Correlation
to other
scales
disorder in a
commercially insured
population
Kennedy
et al. [44]
Work, social, and family
disabilities of subjects
with anxiety and
depression
RCT (post
hoc)
SDS SDS work 
Depression/
Anxiety
Kessler et al.
[3]
Prevalence and effects
of mood disorders on
work performance in a
nationally
representative sample
of US workers
OS HPQ QIDS-SR
(depression)
HPQ 
(Depression;
Bipolar
disorders)
Kessler et al.
[45]
Comparative and
interactive effects of
depression relative to
other health problems
on work performance in
the workforce of a large
employer
Retro-
spective
claims
database
þ survey
data
HPQ HPQ 
(Depre-
ssion;
Bipolar
disorders)
Knoth et al.
[46]
Effect of inadequate
response to treatment
in patients with
depression
OS The WPAI
questionnaire
SF-8 The WPAI
question-
naire
 responder /
partial
responder /
non-
responder
Lam et al. [21] A new clinical rating
scale for work absence
and productivity:
validation in patients
with major depressive
disorder
OS LEAPS, HPQ,
SDS work
QIDS-SR
(depression)
LEAPS 
depression
severity
LEAPS  (SDS work;
HPQ Global Work
Performance)
Lee [47] Loss of productivity due
to depression among
Korean employees
OS SPS SPS 
Depression
Lerner et al.
[9]
The clinical and
occupational correlates
of work productivity
loss among employed
patients with
depression
OS WLQ PHQ-9
(depression),
SF-12
WLQ (output,
time,
mental)
 Depression
WLQ (output,
time, mental,
physical)
 Depression
severity
Lerner et al.
[30]
Unemployment, job
retention, and
productivity loss among
employees with
depression
OS WLQ PHQ-9
(depression)
WLQ
(physical,
output, time,
mental)
 Depression
Lerner et al.
[48]
Work performance of
employees with
depression: the impact
of work stressors
OS WLQ PHQ-9
(depression),
SF-12
WLQ
 Depression
Lin et al. [49] Can depression
treatment in primary
RCT SDS SDS
work
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Table 3 – (continued)
Reference Title Type of
study
Productivity
scale
Other
scale
Result by
presence of
disorder
Result by
severity of
disorder
Result by
evolution of
disorder
Result by
treatment
arm
Correlation
to other
scales
care reduce disability? A
stepped care approach
SCL-20
(depression),
SF-36
McMorris
et al. [50]
Workplace productivity,
employment issues, and
resource utilization in
patients with bipolar I
disorder
OS EWPS EWPS 
Bipolar I
disorder
Olley et al.
[51]
Persistence of
psychiatric disorders in
a cohort of HIV/AIDS
patients in South Africa:
a 6-mo follow-up study
OS SDS SDS work
 Depression
Sanderson
et al. [5]
Which presenteeism
measures are more
sensitive to depression
and anxiety?
OS WLQ, SPS PHQ-9
(depression)
WLQ (output,
time,
mental)
 Depression
severity
WLQ  Remission;
SPS  Remission
Sheehan and
Sheehan
[32]
Assessing treatment
effects in clinical trials
with the discan metric
of the SDS
Review SDS SDS work
 Depression
SDS work
Snedecor
et al. [52]
Economic outcomes of
eszopiclone treatment
in insomnia and
comorbid major
depressive disorder
RCT WLQ HDRS
(depression),
SF-36
WLQ
Soares et al.
[53]
Assessing the efficacy of
desvenlafaxine for
improving functioning
and well-being outcome
measures in patients
with major depressive
disorder: a pooled
analysis of nine double-
blind, placebo-
controlled, 8-wk clinical
trials
Pooled
RCTs
SDS WHO-5
(psycho-
logical well-
being),
MADRS
(depression),
HDRS
(depression)
SDS work
Stamouli
et al. [54]
Escitalopram in clinical
practice in Greece:
treatment response and
tolerability in depressed
patients
Open
label
surveil-
lance
study
SDS MADRS
(depression),
CGI
SDS work 
Improvement
Stewart et al.
[4]
Cost of lost productive
work time among US
workers with
depression
OS WHI
Wang et al. [8] Chronic medical
conditions and work
performance in the
health and work
performance
OS HPQ
V
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Table 3 – (continued)
Reference Title Type of
study
Productivity
scale
Other
scale
Result by
presence of
disorder
Result by
severity of
disorder
Result by
evolution of
disorder
Result by
treatment
arm
Correlation
to other
scales
questionnaire
calibration surveys
Wang et al.
[55]
Telephone screening,
outreach, and care
management for
depressed workers and
impact on clinical and
work productivity
outcomes: a
randomized controlled
trial
RCT HPQ QIDS-SR
(depression)
AIDS, acquired immunodeficiency syndrome; BFSQ, Bipolar Functional Status Questionnaire; CGI, Clinical Global impression; EQ-5D, EuroQol five-dimensional questionnaire; EWPS, Endicott
Work Productivity Scale; HDRS, Hamilton Depression Rating Scale; HPQ, Health and Work Performance Questionnaire; LEAPS, Lam Employment Absence and Productivity Scale; MADRS,
Montgomery-A˚sberg Depression Rating Scale; MDQ, Mood Disorder Questionnaire; MINI, Mini Neuropsychiatric Diagnostic Interview; OS, observational study; PCP, PHQ-9, Patient Health
Questionnaire 9; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; RCT, randomized clinical trial; SAS-SR, Social Adjustment Scale Self-Report; SCL-20, symptom checklist-
20; SDS, the Sheehan Disability Scale; SF-12, Medical Outcome Study Short Form 12 questions; SF-8, Medical Outcome Study Short Form 8 questions; SF-36, short form 36 health survey; SPS,
Stanford Presenteeism Scale; WHI, Work and Health Interview; WHO-5, well-being index; WLQ, Work Limitations Questionnaire; WPAI, Work Productivity and Activity Impairment.
* Indicates that significant differences were shown between treatment groups on the productivity scale.
† HPQ is used to identify self-reported health status and in particular the presence of psychological distress.
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VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 4 8 – 1 1 6 1 1159study type, objective, study design, productivity scale(s) included,
other rating scales (depressive symptoms, health-related quality
of life), assessment dates, and results. Four types of results were
considered in each study: (1) results by treatment arms, (2) results
by health state (symptom severity level), (3) correlation to other
scales, and (4) use of monetization and methods applied. Studies
on the SDS were restricted to those that actually reported results
on the work domain.Results
Only 31 studies discussing the use of productivity instruments in
individuals with mood disorders were retrieved, the majority of
which (74%) were observational studies (prospective cohorts,
retrospective claims databases complemented with a survey to
assess productivity loss or workplace studies). Twelve studies
considered the SDS and explicitly reported and discussed results
on the work domain. The WLQ and the HPQ were used in five
studies. The other productivity instruments appeared in no more
than two studies each. Among the four categories of results
considered, the majority (68%) of articles reported results on
presenteeism instruments by health state or presence/absence of
symptoms of mood disorders. An overview of the available
information in each of the selected studies is presented in
Table 3 [3–5,7–9,13,18,21,30,32,35,37–55].
Overall, results from the retrieved studies showed presentee-
ism scales to be sufficiently sensitive to demonstrate consistently
higher at-work productivity loss in the presence of symptoms of
mood disorders, and in depression in particular, compared with
the performance of employees with no symptoms. The HPQ,
WLQ, SDS, SPS [40], and EWPS [18] clearly showed that employees
with mood disorders presented higher productivity loss than did
employees without mood disorders. Significantly more impair-
ment (approximately 35% productivity reduction in output, time,
and mental-interpersonal demand) was observed by using the
WLQ in employees with depressive symptoms [12,30,48]. Excess
productivity loss was estimated on the basis of the HPQ in a
nationally representative survey of mental disorders in the US
population. This amounted to 18.2 workdays per year for employ-
ees with major depressive disorders and 35.3 days for employees
with bipolar disorders [3].
In addition, studies using several of these instruments have
demonstrated that at-work productivity loss increases with
increasing severity of symptoms. Impairment as measured by
LEAPS and WLQ time, WLQ mental-interpersonal, and WLQ
output scales increases with the severity of depression [5,21,30].
Arbuckle et al. [35] studied the psychometric properties of the
SDS in bipolar disorder and demonstrated that work impairment
increases with increasing severity.
Improvement in symptoms or improvement in health condition
and improvement in productivity were evaluated for theWLQ, SPS-6,
and SDS in four studies. According to Sanderson et al. [5], remission
of symptoms was associated with improvements on WLQ output
demands domain (10.9-point improvement at 6 months; P ¼ 0.006)
and on the SPS-6 (2.2-point improvement at 6 months; P ¼ 0.033) in a
community sample. No significant improvements were measured on
the other WLQ domains [7]. Another study, designed to estimate
remission rates in primary care [37], demonstrated that failure to
achieve remission of symptoms was associated with higher impair-
ment on the SDS work domain (5 vs. 1.6; Po 0.001).
Three articles reported results of presenteeism scales by
treatment group. A pooled analysis of RCTs in major depressive
disorders comparing desvenlafaxine with placebo [53] reported a
significant difference on the SDS work domain for all doses of
desvenlafaxine versus placebo (between 0.6 and 0.8 compared
with placebo) together with lower disability assessed by SDS totalscore. Wang et al. [55] used the HPQ to compare care management
and telephone therapy versus usual care in 604 employees
identified as having significant depression and who were covered
by a managed behavioral health plan. The HPQ score in terms of
effective hours worked was significantly higher in the interven-
tion group at 6 and 12 months (3 hours more per week at 6
months and 3.3 hours per week at 12 months). Conversely, there
was no difference in on-the-job work performance between the
two groups at 6 or 12 months. In a pharmacoeconomic analysis
conducted alongside a randomized clinical trial comparing eszo-
piclone þ fluoxetine versus fluoxetine þ placebo in patients with
comorbid insomnia and major depressive disorders, no difference
between the two treatment groups was reported on the WLQ [52].
Few studies reported data on how presenteeism instruments
correlate to symptomatic rating scales and health-related quality of
life. As part of the validation of LEAPS, correlations between LEAPS
and the SDS work and the HPQ global work performance domains
were reported. The results showed a high correlation between the
LEAPS score and both the HPQ (r ¼ 0.79; Po 0.01) and the SDS work
domain (0.63; Po 0.01). In the study by Arbuckle at al. [35]
reviewing the psychometric properties of the SDS in patients with
bipolar disorder, the SDS work domain showed a high correlation to
SDS family (r ¼ 0.71; Po 0.0001) and SDS social (r ¼ 0.76;
Po 0.0001) domains and to the WPAI questionnaire overall work
impairment (r ¼ 0.55; Po 0.0001), the mental component score
from the SF-36 (r ¼ 0.43; Po 0.0001), and the EuroQoL-5 dimen-
sion (EQ-5D questionnaire; r ¼ 0.46; Po 0.0001). In patients seek-
ing treatment for a major depressive episode in an outpatient
setting and among nonpatients in the community, fairly high
correlations were reported between the EWPS and the Hamilton
Rating Scale for Depression (between 0.27 and 0.61) [18].
Four studies translated presenteeism into monetary units.
Stewart et al. [27] estimated the costs of depression to the US
workforce by calculating lost productive time by using the Work
and Health Interview and applying employee wages to obtain costs
of productivity loss. This article concluded that depression among
US workers was associated with an excess cost of $31 billion per
year in 2002. At-work lost productivity accounted for 81% of the
total cost. Kessler et al. [3] evaluated the impact of major depressive
disorder and bipolar disorder on lost productivity, and on presen-
teeism in particular. Presenteeism estimates derived from the HPQ
were converted into lost-day equivalents and converted into a
salary metric by applying wages increased by 25% to include fringe
benefits. Major depressive disorders and bipolar disorders, respec-
tively, resulted in lost time due to presenteeism of 18.2 and 35.3
days per individual per year, which translate to $2691 and $5184 per
individual per year. On the basis of the WLQ index, hourly wage,
and average number of hours worked per week, Snedecor et al. [52]
estimated the change from baseline in costs associated with
presenteeism and added these to total medical costs and absentee-
ism costs. The savings over 8 weeks associated with lower pre-
senteeism for eszopiclone þ fluoxetine compared with placebo þ
fluoxetine ($82) partially offset the additional acquisition costs of
eszopiclone ($209). It should be noted, however, that while differ-
ences were observed on the WLQ between the two treatment
strategies, these were not statistically significant, and while no
minimally important difference in the level of impairment has been
established for the WLQ, the reported difference in this trial (o 1%
of lost productivity while at work) is very small. Further information
regarding the minimal important difference on the WLQ productiv-
ity loss score is needed to provide definite conclusions.Discussion/Conclusions
Several instruments are available to researchers aimed at mea-
suring productivity loss due to presenteeism, all of which are
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 4 8 – 1 1 6 11160applicable to mood disorders. Limited evidence exists, however,
on their actual use in this disease area, with the exception of the
SDS, a scale that cannot be fully classified as a productivity
instrument. Although psychometric properties have been verified
for most instruments in the general population, little evidence
has been generated in mood disorders and only four instruments
are at least partially validated in mood disorders. Furthermore,
even in a general context, responsiveness is not well documented
for most of the scales.
Most of the available instruments are able to show differences
in productivity loss between individuals with or without symp-
toms and allow researchers to detect improvement in productivity
associated with health improvements. Nonetheless, the ability to
detect differences between treatments or interventions in a
randomized setting has not been demonstrated for any of the
instruments. While this may be due, in part, to a lack of
sensitivity of the instruments, it is probably due to design
characteristics such as too short a time horizon and the lack of
statistical power to conclude that there was a significant differ-
ence between the interventions. This lack of statistical power is
expected in clinical trials because these are not initially powered
to detect a difference in presenteeism but only on the primary end
point, which often is a measure of clinical efficacy. One of the
studies retrieved in this review was a pooled analysis, confirming
the benefit of performing the analysis on presenteeism instru-
ments with an increase in the statistical power [53]. Furthermore,
the low number of studies that report results on presenteeism
instruments suggests that these productivity estimates are often
not evaluated. This would confirm that it is rare to detect
between-treatment differences in presenteeism by using these
instruments, and suggests that much larger sample sizes are
required to demonstrate a significant difference by using presen-
teeism instruments compared with symptomatic rating scales.
Few studies have used productivity instruments to estimate
the cost of presenteeism, despite the fact that presenteeism is
known to be one of the major cost drivers in mood disorders [4]
and that monetization is theoretically possible for most of the
selected instruments. Similar to the results reported in the
review by Lerner and Henke [12], the instruments were most
often used in an observational setting such as the workplace, or
in a clinical setting, and very little information is published
regarding the use of these instruments in an RCT setting. The
lack of productivity estimates in clinical trials could be due to a
number of factors. First, it is possible that some relevant studies
have not been retrieved because the search strategy may have
failed to identify studies in which the use of a presenteeism scale
is not explicitly mentioned in the abstract. Second, results from
the measurement of lost productivity may not necessarily have
been reported in the published studies, particularly if the results
were negative or uninteresting. Third, the lack of productivity
estimates from clinical trials could be due to a failure to publish
findings from trials in which the primary objective was to
measure changes in productivity if this objective was not met.
Further investigations using clinical trial registries are needed to
track clinical trials that have assessed lost productivity in an
attempt to identify additional published results for further
analysis. Finally, the RCT context may not be fully suited for
the use of productivity loss instruments because of the limited
number of patients, short time horizon, and heterogeneity
caused by the participation of patients from different countries.
Recommendations as to which productivity scale is best suited
to estimate the cost of presenteeism in mood disorders should be
based primarily on instrument properties because of the limited
experiential evidence. The HPQ may be the best option for
measuring and valuing productivity because this instrument
establishes an objective measure of productivity in a workplace
context. However, this questionnaire lacks the ability to capturedifferent levels of presenteeism on different days, and its com-
plexity may prevent its use in RCTs, even with the version adapted
to this setting. Its use and efficiency in clinical trials should be
further assessed to allow more definite recommendations on the
usefulness of this instrument in the area of mood disorders.
Other tools such as the WLQ, the WPAI questionnaire, LEAPS, or
SF-HLQ seem to be more adapted to the clinical trial context
because they are shorter and more straightforward to complete.
WLQ presents important evidence in mood disorders and presents
high validity in this disease area although some ambiguity remains
related to the monetization scoring. Little evidence exists on the use
of the WPAI questionnaire in mood disorders, although it has been
used in numerous disease areas, including anxiety disorders [56].
This same limitation should be addressed for SF-HLQ. Nonetheless,
the use of cognitive debriefing during the development of the WPAI
questionnaire is a piece of evidence that supports its use in patients
with mood disorders, whereas such information was not retrieved
for the SF-HLQ. LEAPS has the advantage of having been developed
specifically for depression and of being validated for this condition,
but its amenability for monetization is still under investigation.
Despite its wide use in mood disorders and its good properties, the
SDS cannot be considered a productivity scale. Other scales such as
the EWPS are validated in this specific disease area, but they are of
limited use for estimating the cost of presenteeism because conver-
sion into monetary unit is not possible.
To be able to make recommendations as to the use of specific
instruments in clinical trials and observational studies in mood
disorders, further empirical data are needed. Further research is
also needed in the following three areas: (1) Full documentation
as to the responsiveness will give researchers important data for
sample size calculations for designing RCTs or observational
studies; (2) The relevance of the use of these instruments in
clinical trials should be further investigated, and guidance should
be provided regarding appropriate study design (study duration,
population to include, single- or multicountry study) as well as
advice on the selection of the most appropriate scale; and (3)
Although all the instruments measuring presenteeism were able
to detect an excess in productivity loss in patients with symp-
toms of mood disorders compared with patients without symp-
toms, the impact of mood disorder on self-rating evaluations is
not well documented and, at this time, it is not possible to
determine all the potential biases in reported estimates. Lerner
and Henke [12] concluded that self-report estimates from the
WLQ reported by depressed workers were as accurate as the ones
reported by nondepressed workers. Additional evidence is
needed regarding the comparison between self-report assess-
ments and objective data for the other presenteeism question-
naires and the validity of the conversion algorithm to generate
monetary estimates. This would ensure that unbiased estimates
of productivity loss in mood disorder could be generated and
reinforce the credibility of economic evaluations in this patient
population conducted from a societal perspective.
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